{
    "id": 14252,
    "cites": 24,
    "cited_by": 0,
    "reference": [
        "Berry, Steve (1994) Estimating Discrete Choice Models of Product Differentiation RAND Journal of Economics 25, pp. 242-262.",
        "Ching, Andrew (2005) Consumer Learning and Heterogeneity: Dynamics of Demand for Prescription Drugs After Patent Expiration University of Toronto Working Paper.",
        "Coscelli, Andrea and Matthew Shum (2004) An Empirical Model of Learning and Patient Spillovers in New Drug Entry Journal of Econometrics.",
        "Crawford, Greg and Matthew Shum (2005) Uncertainty and Learning in Pharmaceutical Demand  Econometrica.",
        "Dai, Carolanne; Randall S. Stafford and Caleb G. Alexander (2005) National Trends in Cyclooxygenase-2 Inhibitor Use Since Market Release: Nonnselective Diffusion of a Selectively Cost-Effective Innovation. Achieves of Internal Medicine Jan. 24, 2005.",
        "Dayton, M. and G. Macready (1988) Concomitant-Variable Latent Class Models. Journal of the American Statistical Association 83: 173-178.",
        "DeGroot, M. (1970) Optimal Statistical Decisions New York: mcGraw-Hill.",
        "Erdem, T. and M. Keane (1996) Decision-making Under Uncertainty: Capturing Dynamic Brand Choice Processes in Turbulent Consumer Goods Market Marketing Science, 15,120.",
        "Fontanarosa, Phil B. , Drummond Rennie and Catherine D. DeAngelis Postmarketing Surveillance Lack of Vigilance, Lack of Trust the Journal of American Medical Association Dec. 1, 2004, volume 292 (21).",
        "Food and Drug Administration (2005) Analysis and recommendations for Agency action regarding non-steoroidal anti-inflammatory drugs and cardiovascular risk FDA Memorandum as of April 6, 2005.",
        "GAO (2006) Drug Safety: Improvement Needed in FDAs Postmarket Decision-making and Oversight Process GAO-06-402.",
        "Grassley C. (2005) S.930: A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to drug safety, and for other purposes. 109th Congress.",
        "TOM (Institute of Medicine) (2007): The Future of Drug Safety: Promoting and Protecting the Health of the Public. National Academies Press.",
        "Lilien, Gary L.; Philip Kotler; and K. Sridhar Moorthy (1992) Marketing Models, Englewood Cliffs, NJ: Prentice Hall.",
        "McFadden, Daniel (1973) Conditional Logit Analysis of Qualitative Choice Behavior, inP. Zarembka (ed.) Frontiers in Econometrics, Academic Press, New York.",
        "Narayanan, Sridhar; Puneet Manchanda; and Pradeep K. Chintagunta (2005) Temporal Differences in the Role of Marketing Communication in New Product Categories Journal of Marketing Research.",
        "NCL (National Consumers League) (2005) Comments of the National Consumers League to DKT. No. 2005N-0394, Communication of Drug Safety Information.",
        "Nelson, P. (1974) Advertising as Information Journal of Political Economy 82, 729-753.",
        "Ray, Wayne A. and C. Michael Stein (2006) Reform of Drug Regulation Beyond an Independent Drug-Safety Board The New England Journal of Medicine Jan. 12, 2006, Volume 354: 194-201.",
        "Slater, Eve E. (2005) Todays FDA The New England Journal of Medicine Jan. 20, 2005, Volume 352: 293-297.",
        "Tufts Center for the Study of Drug Development (TCSDD 2004): FDA Requested postmarketing studies in 73% of recent new drug approvals Impact Report: Analysis and Insight into Critical Drug Development Issues Vol. 6, No. 4, July/August 2004.",
        "Berndt, E.R., L. Bui, D.R. Reiley, and G.L. Urban (1995): Information, Marketing, and Pricing in the US Antiulcer Drug Market American Economic Review, 85(2), pp. 100105.",
        "Ackerberg, Daniel (2003) Advertising, Learning, and Consumer Choice in Experience Good Markets: An Empirical Examination International Economic Review, 44, pp. 1007-1040.",
        "Ackerberg, Daniel (2001) Empirically Distinguishing Informative and Prestige Effects of Advertising RAND Journal of Economics 32, pp 316-333."
    ]
}